Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1
暂无分享,去创建一个
B. Bosch | M. Wiebe | G. van Amerongen | B. Haagmans | M. Saloheimo | M. Vitikainen | I. Albulescu | A. Osterhaus | M. Ciurkiewicz | Mark Emalfarb | R. Tchelet | Imke Steffen | F. Kaiser | W. Baumgärtner | M. Gonzalez-Hernandez
[1] Y. Ramot,et al. Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge , 2022, Vaccines.
[2] W. Baumgärtner,et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters , 2022, Nature Communications.
[3] A. A. Sergeev,et al. Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines? , 2022, Viruses.
[4] Y. Ramot,et al. Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1 Thermothelomyces Heterothallica Protein Expression Platform , 2022, Toxicologic pathology.
[5] F. Grosveld,et al. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern , 2022, bioRxiv.
[6] G. Rimmelzwaan,et al. Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections—an Open Observational Study in Lower Saxony, Germany , 2022, Microbiology spectrum.
[7] B. Pulendran,et al. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice , 2022, bioRxiv.
[8] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[9] A. Hernandez,et al. A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice , 2022, Vaccine.
[10] R. Delgado,et al. Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals , 2021, The Journal of infectious diseases.
[11] B. Bošnjak,et al. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents , 2021, Frontiers in Immunology.
[12] G. Chinea,et al. In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI–MS spectrum , 2021, Analytical and Bioanalytical Chemistry.
[13] B. Bosch,et al. Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021 , 2021, Biologicals.
[14] Laura E. Crowell,et al. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice , 2021, Proceedings of the National Academy of Sciences.
[15] M. Ciccozzi,et al. The variants question: What is the problem? , 2021, Journal of medical virology.
[16] Beiming Yu,et al. SARS-CoV-2: Origin, Evolution, and Targeting Inhibition , 2021, Frontiers in Cellular and Infection Microbiology.
[17] Lisa E. Gralinski,et al. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung , 2021, Nature Communications.
[18] W. Baumgärtner,et al. Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2 , 2021, Frontiers in Immunology.
[19] K. Becker,et al. Vascular Inflammation Is Associated with Loss of Aquaporin 1 Expression on Endothelial Cells and Increased Fluid Leakage in SARS-CoV-2 Infected Golden Syrian Hamsters , 2021, Viruses.
[20] L. Stamatatos,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.
[21] A. Iafrate,et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.
[22] Jihun Lee,et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein , 2021, Nature communications.
[23] J. Min,et al. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351 , 2021, mAbs.
[24] R. Kane,et al. Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization , 2020, Communications biology.
[25] R. Owens,et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 , 2020, Nature Structural & Molecular Biology.
[26] T. Kuiken,et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.
[27] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[28] A. M. Leontovich,et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.
[29] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[30] M. Howarth,et al. Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination , 2018, ACS nano.
[31] A. Gusakov,et al. Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1 , 2011 .